Y Becouarn

Summary

Affiliation: Institut Bergoni
Country: France

Publications

  1. ncbi Value of microsatellite instability typing in detecting hereditary non-polyposis colorectal cancer. A prospective multicentric study by the Association Aquitaine Gastro
    Yves Becouarn
    Département d Oncologie Digestive, Institut Bergonie, Bordeaux, France
    Gastroenterol Clin Biol 29:667-75. 2005
  2. ncbi Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers
    Y Becouarn
    Institut Bergonie, Bordeaux, France
    J Clin Oncol 16:2739-44. 1998
  3. ncbi Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients
    Y Becouarn
    Department of Digestive Oncology, Regional Cancer Center, Institut Bergonie, 229 Cours de l Argonne, 33076 Bordeaux Cedex, France
    J Clin Oncol 19:4195-201. 2001
  4. ncbi Oxaliplatin: available data in non-colorectal gastrointestinal malignancies
    Y Becouarn
    Department of Digestive Oncology, Institut Bergonie, Regional Cancer Centre, 229, cours de l Argonne, F 33076 Bordeaux cedex, France
    Crit Rev Oncol Hematol 40:265-72. 2001
  5. ncbi A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study
    Y Becouarn
    Department of Digestive Oncology, Institut Bergonie, Regional Cancer Center, Bordeaux, France
    Ann Oncol 18:2000-5. 2007
  6. ncbi Phase II study of a 5-fluorouracil, teniposide and mitomycin-C combination chemotherapy in advanced colorectal carcinomas
    Y Becouarn
    , Bordeaux, France
    Tumori 74:75-7. 1988
  7. ncbi Comparison of hepatic recurrences after resection or intraoperative radiofrequency ablation indicated by size and topographical characteristics of the metastases
    F Leblanc
    Digestive Tumours Unit, Institut Bergonie, Comprehensive Cancer Centre, 229 Cours de l Argonne, 33076 Bordeaux, France
    Eur J Surg Oncol 34:185-90. 2008
  8. ncbi [Radiofrequency ablation in the treatment of liver and lung tumors]
    J Palussiere
    Départements de radiologie, Institut Bergonie, Centre Regional de Lutte Contre le Cancer, 229, cours de l Argonne, 33076 Bordeaux Cedex, France
    Bull Cancer 96:1099-109. 2009
  9. ncbi Surgical treatment of liver metastases by radiofrequency ablation, resection, or in combination
    S Evrard
    The Digestive Oncology Unit, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France
    Eur J Surg Oncol 30:399-406. 2004
  10. ncbi Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary
    Y Becouarn
    Fondation Bergonie, Bordeaux, France
    Eur J Cancer Clin Oncol 25:861-5. 1989

Collaborators

Detail Information

Publications12

  1. ncbi Value of microsatellite instability typing in detecting hereditary non-polyposis colorectal cancer. A prospective multicentric study by the Association Aquitaine Gastro
    Yves Becouarn
    Département d Oncologie Digestive, Institut Bergonie, Bordeaux, France
    Gastroenterol Clin Biol 29:667-75. 2005
    ....
  2. ncbi Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers
    Y Becouarn
    Institut Bergonie, Bordeaux, France
    J Clin Oncol 16:2739-44. 1998
    ..To evaluate the objective tumor response rate and safety profile of oxaliplatin when administered to patients with previously untreated metastatic colorectal adenocarcinoma...
  3. ncbi Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients
    Y Becouarn
    Department of Digestive Oncology, Regional Cancer Center, Institut Bergonie, 229 Cours de l Argonne, 33076 Bordeaux Cedex, France
    J Clin Oncol 19:4195-201. 2001
    ....
  4. ncbi Oxaliplatin: available data in non-colorectal gastrointestinal malignancies
    Y Becouarn
    Department of Digestive Oncology, Institut Bergonie, Regional Cancer Centre, 229, cours de l Argonne, F 33076 Bordeaux cedex, France
    Crit Rev Oncol Hematol 40:265-72. 2001
    ..To date, oxaliplatin appears as a real candidate for clinical development in this field...
  5. ncbi A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study
    Y Becouarn
    Department of Digestive Oncology, Institut Bergonie, Regional Cancer Center, Bordeaux, France
    Ann Oncol 18:2000-5. 2007
    ..To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer...
  6. ncbi Phase II study of a 5-fluorouracil, teniposide and mitomycin-C combination chemotherapy in advanced colorectal carcinomas
    Y Becouarn
    , Bordeaux, France
    Tumori 74:75-7. 1988
    ..Chemotherapy was stopped once owing to severe hematologic toxicity. With the doses and schedule used, the drug combination appears to have minimal activity in advanced colorectal cancer...
  7. ncbi Comparison of hepatic recurrences after resection or intraoperative radiofrequency ablation indicated by size and topographical characteristics of the metastases
    F Leblanc
    Digestive Tumours Unit, Institut Bergonie, Comprehensive Cancer Centre, 229 Cours de l Argonne, 33076 Bordeaux, France
    Eur J Surg Oncol 34:185-90. 2008
    ..Intraoperative use of radiofrequency ablation (IRFA) to treat liver metastases is controversial. The aim of this study was to compare local recurrence rate and survival after IRFA versus resection...
  8. ncbi [Radiofrequency ablation in the treatment of liver and lung tumors]
    J Palussiere
    Départements de radiologie, Institut Bergonie, Centre Regional de Lutte Contre le Cancer, 229, cours de l Argonne, 33076 Bordeaux Cedex, France
    Bull Cancer 96:1099-109. 2009
    ..Nevertheless prospective randomized trials to compare RF with surgery are difficult to achieve, prospective studies are needed to better evaluate the technique...
  9. ncbi Surgical treatment of liver metastases by radiofrequency ablation, resection, or in combination
    S Evrard
    The Digestive Oncology Unit, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France
    Eur J Surg Oncol 30:399-406. 2004
    ..The aim of this study was to determine the feasibility and value using RFA, resection or in combination to cure liver metastases of colorectal or other origin...
  10. ncbi Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary
    Y Becouarn
    Fondation Bergonie, Bordeaux, France
    Eur J Cancer Clin Oncol 25:861-5. 1989
    ..Such a regimen is of limited efficacy, has a non-negligible toxicity and appears of little interest in such a palliative situation...
  11. ncbi [Systematic review: value of perioperative chemotherapy in the management of resectable rectal adenocarcinoma (brief report)]
    Y Becouarn
    Oncologue médical, Institut Bergonie, Bordeaux, France
    Bull Cancer 95:717-34. 2008
    ....
  12. ncbi Efforts to improve local control in rectal cancer compromise survival by the potential morbidity of optimal mesorectal excision
    Christophe Laurent
    Department of Surgery, , Bordeaux, France
    J Am Coll Surg 203:684-91. 2006
    ..Efforts are necessary to decrease postoperative morbidity in surgical treatment of rectal cancer...